β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10

Chunmei Fu, Xinjun Liang, Weiguo Cui, Julia L. Ober-Blöbaum, Joseph Vazzana, Protul A. Shrikant, Kelvin P. Lee, Björn E. Clausen, Ira Mellman, Aimin Jiang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Recent studies have demonstrated that β-catenin in DCs serves as a key mediator in promoting both CD4+ and CD8+ T-cell tolerance, although how β-catenin exerts its functions remains incompletely understood. Here we report that activation of β-catenin in DCs inhibits cross-priming of CD8+ T cells by up-regulating mTOR-dependent IL-10, suggesting blocking β-catenin/mTOR/IL-10 signaling as a viable approach to augment CD8+ T-cell immunity. However, vaccination of DC-β-catenin-/- (CD11c-specific deletion of β-catenin) mice surprisingly failed to protect them against tumor challenge. Further studies revealed that DC-β-catenin-/- mice were deficient in generating CD8+ T-cell immunity despite normal clonal expansion, likely due to impaired IL-10 production by β-catenin-/- DCs. Deletion of β-catenin in DCs or blocking IL-10 after clonal expansion similarly led to reduced CD8+ T cells, suggesting that β-catenin in DCs plays a positive role in CD8+ T-cell maintenance postclonal expansion through IL-10. Thus, our study has not only identified mTOR/IL-10 as a previously unidentified mechanism for β-catenin-dependent inhibition of cross-priming, but also uncovered an unexpected positive role that β-catenin plays in maintenance of CD8+ T cells. Despite β-catenin's opposite functions in regulating CD8+ T-cell responses, selectively blocking β-catenin with a pharmacological inhibitor during priming phase augmented DC vaccine-induced CD8+ T-cell immunity and improved antitumor efficacy, suggesting manipulating β-catenin signaling as a feasible therapeutic strategy to improve DC vaccine efficacy.

Original languageEnglish (US)
Pages (from-to)2823-2828
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number9
DOIs
StatePublished - Mar 3 2015

Fingerprint

Cross-Priming
Catenins
Interleukin-10
Dendritic Cells
Maintenance
T-Lymphocytes
Immunity
Vaccines

Keywords

  • Beta-catenin
  • CD8 T-cell immunity
  • Dendritic cells
  • IL-10
  • MTOR

ASJC Scopus subject areas

  • General

Cite this

β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. / Fu, Chunmei; Liang, Xinjun; Cui, Weiguo; Ober-Blöbaum, Julia L.; Vazzana, Joseph; Shrikant, Protul A.; Lee, Kelvin P.; Clausen, Björn E.; Mellman, Ira; Jiang, Aimin.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 9, 03.03.2015, p. 2823-2828.

Research output: Contribution to journalArticle

Fu, Chunmei ; Liang, Xinjun ; Cui, Weiguo ; Ober-Blöbaum, Julia L. ; Vazzana, Joseph ; Shrikant, Protul A. ; Lee, Kelvin P. ; Clausen, Björn E. ; Mellman, Ira ; Jiang, Aimin. / β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 9. pp. 2823-2828.
@article{1296d9a7283d4572b2978c3d87fe9a58,
title = "β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10",
abstract = "Recent studies have demonstrated that β-catenin in DCs serves as a key mediator in promoting both CD4+ and CD8+ T-cell tolerance, although how β-catenin exerts its functions remains incompletely understood. Here we report that activation of β-catenin in DCs inhibits cross-priming of CD8+ T cells by up-regulating mTOR-dependent IL-10, suggesting blocking β-catenin/mTOR/IL-10 signaling as a viable approach to augment CD8+ T-cell immunity. However, vaccination of DC-β-catenin-/- (CD11c-specific deletion of β-catenin) mice surprisingly failed to protect them against tumor challenge. Further studies revealed that DC-β-catenin-/- mice were deficient in generating CD8+ T-cell immunity despite normal clonal expansion, likely due to impaired IL-10 production by β-catenin-/- DCs. Deletion of β-catenin in DCs or blocking IL-10 after clonal expansion similarly led to reduced CD8+ T cells, suggesting that β-catenin in DCs plays a positive role in CD8+ T-cell maintenance postclonal expansion through IL-10. Thus, our study has not only identified mTOR/IL-10 as a previously unidentified mechanism for β-catenin-dependent inhibition of cross-priming, but also uncovered an unexpected positive role that β-catenin plays in maintenance of CD8+ T cells. Despite β-catenin's opposite functions in regulating CD8+ T-cell responses, selectively blocking β-catenin with a pharmacological inhibitor during priming phase augmented DC vaccine-induced CD8+ T-cell immunity and improved antitumor efficacy, suggesting manipulating β-catenin signaling as a feasible therapeutic strategy to improve DC vaccine efficacy.",
keywords = "Beta-catenin, CD8 T-cell immunity, Dendritic cells, IL-10, MTOR",
author = "Chunmei Fu and Xinjun Liang and Weiguo Cui and Ober-Bl{\"o}baum, {Julia L.} and Joseph Vazzana and Shrikant, {Protul A.} and Lee, {Kelvin P.} and Clausen, {Bj{\"o}rn E.} and Ira Mellman and Aimin Jiang",
year = "2015",
month = "3",
day = "3",
doi = "10.1073/pnas.1414167112",
language = "English (US)",
volume = "112",
pages = "2823--2828",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10

AU - Fu, Chunmei

AU - Liang, Xinjun

AU - Cui, Weiguo

AU - Ober-Blöbaum, Julia L.

AU - Vazzana, Joseph

AU - Shrikant, Protul A.

AU - Lee, Kelvin P.

AU - Clausen, Björn E.

AU - Mellman, Ira

AU - Jiang, Aimin

PY - 2015/3/3

Y1 - 2015/3/3

N2 - Recent studies have demonstrated that β-catenin in DCs serves as a key mediator in promoting both CD4+ and CD8+ T-cell tolerance, although how β-catenin exerts its functions remains incompletely understood. Here we report that activation of β-catenin in DCs inhibits cross-priming of CD8+ T cells by up-regulating mTOR-dependent IL-10, suggesting blocking β-catenin/mTOR/IL-10 signaling as a viable approach to augment CD8+ T-cell immunity. However, vaccination of DC-β-catenin-/- (CD11c-specific deletion of β-catenin) mice surprisingly failed to protect them against tumor challenge. Further studies revealed that DC-β-catenin-/- mice were deficient in generating CD8+ T-cell immunity despite normal clonal expansion, likely due to impaired IL-10 production by β-catenin-/- DCs. Deletion of β-catenin in DCs or blocking IL-10 after clonal expansion similarly led to reduced CD8+ T cells, suggesting that β-catenin in DCs plays a positive role in CD8+ T-cell maintenance postclonal expansion through IL-10. Thus, our study has not only identified mTOR/IL-10 as a previously unidentified mechanism for β-catenin-dependent inhibition of cross-priming, but also uncovered an unexpected positive role that β-catenin plays in maintenance of CD8+ T cells. Despite β-catenin's opposite functions in regulating CD8+ T-cell responses, selectively blocking β-catenin with a pharmacological inhibitor during priming phase augmented DC vaccine-induced CD8+ T-cell immunity and improved antitumor efficacy, suggesting manipulating β-catenin signaling as a feasible therapeutic strategy to improve DC vaccine efficacy.

AB - Recent studies have demonstrated that β-catenin in DCs serves as a key mediator in promoting both CD4+ and CD8+ T-cell tolerance, although how β-catenin exerts its functions remains incompletely understood. Here we report that activation of β-catenin in DCs inhibits cross-priming of CD8+ T cells by up-regulating mTOR-dependent IL-10, suggesting blocking β-catenin/mTOR/IL-10 signaling as a viable approach to augment CD8+ T-cell immunity. However, vaccination of DC-β-catenin-/- (CD11c-specific deletion of β-catenin) mice surprisingly failed to protect them against tumor challenge. Further studies revealed that DC-β-catenin-/- mice were deficient in generating CD8+ T-cell immunity despite normal clonal expansion, likely due to impaired IL-10 production by β-catenin-/- DCs. Deletion of β-catenin in DCs or blocking IL-10 after clonal expansion similarly led to reduced CD8+ T cells, suggesting that β-catenin in DCs plays a positive role in CD8+ T-cell maintenance postclonal expansion through IL-10. Thus, our study has not only identified mTOR/IL-10 as a previously unidentified mechanism for β-catenin-dependent inhibition of cross-priming, but also uncovered an unexpected positive role that β-catenin plays in maintenance of CD8+ T cells. Despite β-catenin's opposite functions in regulating CD8+ T-cell responses, selectively blocking β-catenin with a pharmacological inhibitor during priming phase augmented DC vaccine-induced CD8+ T-cell immunity and improved antitumor efficacy, suggesting manipulating β-catenin signaling as a feasible therapeutic strategy to improve DC vaccine efficacy.

KW - Beta-catenin

KW - CD8 T-cell immunity

KW - Dendritic cells

KW - IL-10

KW - MTOR

UR - http://www.scopus.com/inward/record.url?scp=84924180359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924180359&partnerID=8YFLogxK

U2 - 10.1073/pnas.1414167112

DO - 10.1073/pnas.1414167112

M3 - Article

VL - 112

SP - 2823

EP - 2828

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -